仙琚制药：已同时具备地屈孕酮原料药的自主生产能力

Core Viewpoint - The company has obtained the domestic production drug registration certificate for Dydrogesterone tablets as of May 2025 and has also established its own production capability for Dydrogesterone raw materials [1] Group 1 - The company announced on September 17 that it has received the registration certificate for Dydrogesterone tablets [1] - The company is now capable of independently producing Dydrogesterone raw materials [1]